P2D Bioscience

Executive Summary

P2D Bioscience is a privately held specialty pharmaceutical company headquartered in San Diego, California, dedicated to developing innovative small-molecule therapies for central nervous system (CNS) inflammatory disorders. The company's lead programs target frontotemporal dementia (FTD) and Alzheimer's disease (AD), two devastating neurodegenerative conditions with high unmet medical need. By focusing on the inflammatory component of these diseases, P2D aims to modulate microglial activation and neuroinflammation, offering a potentially disease-modifying approach that complements current symptomatic treatments. Founded in 2016, the company remains in the preclinical stage, leveraging its proprietary platform to advance novel chemical entities through discovery and early development. As a preclinical-stage biotech, P2D's near-term focus is on completing IND-enabling studies and generating robust preclinical proof-of-concept data to support a first-in-human trial. The company is expected to seek partnerships or non-dilutive funding to bridge the gap to clinical development. Key upcoming catalysts include the initiation of IND-enabling toxicology and pharmacokinetic studies, as well as potential presentations of preclinical efficacy data at major neurology conferences. Successful execution of these milestones could significantly de-risk the pipeline and attract strategic interest from larger pharmaceutical companies focused on CNS diseases.

Upcoming Catalysts (preview)

• Q4 2026Initiation of IND-Enabling Toxicology Studies60% success
• Q3 2026Presentation of Preclinical Efficacy Data for Lead Candidate in FTD Models80% success
• TBDAnnouncement of Strategic Partnership or Grant Funding50% success